{"name":"Marker Therapeutics","slug":"marker-therapeutics","ticker":"MRKR","exchange":"NASDAQ","domain":"markertherapeutics.com","description":"Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets. It develops MT-601, which is in Phase 1 trials for the treatment of lymphoma and pancreatic cancer; and MT-401-OTS, which is in a Phase 1 trial for the treatment of acute myeloid leukemia and myelodysplastic syndromes. The company was formerly known as TapImmune, Inc. and changed its name to Marker Therapeutics, Inc. in October 2018. Marker Therapeutics, Inc. was founded in 1999 and is headquartered in Houston, Texas.","hq":"Houston, TX","founded":0,"employees":"5","ceo":"Juan F. Vera","sector":"Oncology / Cell Therapy","stockPrice":1.43,"stockChange":0,"stockChangePercent":0,"marketCap":"$24M","metrics":{"revenue":3546669,"revenueGrowth":-51,"grossMargin":-232.7,"rdSpend":11799154,"netIncome":-12163620,"cash":16068048,"dividendYield":0,"peRatio":-7.5,"fiscalYear":"FY2021"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"MT-401 patent cliff ($0.0B at risk)","drug":"MT-401","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Marker Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Marker Therapeutics reported its financial results for the fourth quarter and full year 2023, with a net loss of $13.4 million for the quarter and $54.6 million for the year.","drugName":"","sentiment":"neutral"},{"date":"2023-11-14","type":"deal","headline":"Marker Therapeutics Announces Collaboration with University of Texas MD Anderson Cancer Center","summary":"Marker Therapeutics announced a collaboration with the University of Texas MD Anderson Cancer Center to develop novel T-cell therapies for the treatment of solid tumors.","drugName":"","sentiment":"positive"},{"date":"2023-09-11","type":"trial","headline":"Marker Therapeutics Announces Positive Interim Results from Phase 1/2 Clinical Trial of MT-401","summary":"Marker Therapeutics announced positive interim results from a Phase 1/2 clinical trial of its lead product, MT-401, in patients with solid tumors.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxQNUhaR1J5V3pQdjM5aVFHWmwyOV9IVVdGeVhIQnpzTnEtTW9vZWtfZlB3SExUMUdhVkNwYzJRTzFTTG5tb0lTRXdtTV94SEp3bmpNQWRJZ1d5M2w2djdnTzNtbVl1MTVzM1F1MkJGcGJVaUljU0Zuc0x1aWlPMncxaTUwUlNoQmt0TVF5el91Nzl4VXBwTDk2eDFOTVFyZUxBYUtRUE1VWmY0ZFpiWVE?oc=5","date":"2026-03-23","type":"earnings","source":"Defense World","summary":"Marker Therapeutics (MRKR) to Release Quarterly Earnings on Monday - Defense World","headline":"Marker Therapeutics (MRKR) to Release Quarterly Earnings on Monday","sentiment":"neutral"},{"date":"2026-03-19","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-03-18","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-12","type":"pipeline","source":"simplywall.st","summary":"Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation - simplywall.st","headline":"Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxQaHNyZWtjVnNRZzctdWE4VDVqNFRlR3oxSE05eGF0ZTB5aUFOTjhNYXc5VDJsUU9ib3NVZ2ozREpDWjhkUnpKZmhGQklhNXNGaUpUN0dwclFIY1kxS1l6bHRaaDh2Q3Q3ZmNtc2dJNnJoT1pIeGNGcVZ5U3BfMmV1VnBxeldPTnF0RWFQVXZuQQ?oc=5","date":"2026-01-08","type":"pipeline","source":"Yahoo Finance","summary":"Zacks Industry Outlook Highlights Soleno Therapeutics, Nektar Therapeutics, Rigel Pharmaceuticals, Ironwood Pharmaceuticals and Marker Therapeutics - Yahoo Finance","headline":"Zacks Industry Outlook Highlights Soleno Therapeutics, Nektar Therapeutics, Rigel Pharmaceuticals, Ironwood Pharmaceutic","sentiment":"neutral"},{"date":"2025-11-14","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-11-13","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-11-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-10-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-08-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-08-16","type":"earnings","source":"simplywall.st","summary":"Marker Therapeutics Second Quarter 2025 Earnings: Beats Expectations - simplywall.st","headline":"Marker Therapeutics Second Quarter 2025 Earnings: Beats Expectations","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxPek1rNGI1eFB1czVJTVN5U1lKanp5S0ZUZXpoOHRsR2FjdE1DR0FkbnV5R2NuNnJWN0tYSlR6VlNYVUI5bnpDSm0yNzVhQWdKNkRET3VheUMzT0VZMElhLU51UHdPakhXMG1xdjNaU3VBZmRVenJ1M1FzODh1cjE5TkR3?oc=5","date":"2025-07-11","type":"pipeline","source":"Yahoo Finance","summary":"Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation - Yahoo Finance","headline":"Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMia0FVX3lxTFBiOThDY3ZISGFjSnZlS0JEQ1kyaDh2ai1TczJDYnBzOVhmSy1adGRaZ2tnNm1kYlJfQTc0QTF1VHNJSWpHX0ZpMXJpcmY5WjRwNkVoTHJGeVUyVFZ5SFBNVTZtVENVS3dSNTFz?oc=5","date":"2021-08-10","type":"earnings","source":"Zacks Investment Research","summary":"What date does MARKER THERAPEUTICS's (MRKR) report Earnings - Earnings Calendar & Announcement - Zacks Investment Research","headline":"What date does MARKER THERAPEUTICS's (MRKR) report Earnings - Earnings Calendar & Announcement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxNQkdPRF9WRjdnd2t4ZmhzY2FXU2ZWT21ROW92SVp3RWR1NF84UGY3SjN1RDNIeW9GWG0tS0RwcENrMXcxQ2tqbTdSVGtoYnZUWnpLeDN2T3Jnci1seF95YUtpVHNXYTN2RzBmakNTNG1kN1p0eExfRnRmYnJ0MGlJWg?oc=5","date":"2020-04-28","type":"pipeline","source":"MarketBeat","summary":"Top Marker Therapeutics (MRKR) Competitors 2026 - MarketBeat","headline":"Top Marker Therapeutics (MRKR) Competitors 2026","sentiment":"neutral"}],"patents":[{"drugName":"MT-401","drugSlug":"multi-tumor-antigen-specific-t-cell-therapy","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bristol Myers Squibb","Merck & Co.","Gilead Sciences"],"therapeuticFocus":["Immuno-oncology","Solid tumors","Hematological malignancies"],"financials":{"source":"sec_edgar+yahoo","revenue":0,"revenuePeriod":"2021-12-31","revenueHistory":[{"value":0,"period":"2021-12-31"},{"value":500000,"period":"2020-12-31"},{"value":213194,"period":"2019-12-31"},{"value":205994,"period":"2018-12-31"},{"value":183064,"period":"2017-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":11799154,"rdSpendHistory":[{"period":"2025-12-31","value":11799154},{"period":"2024-12-31","value":13467845},{"period":"2023-12-31","value":10416789},{"period":"2022-12-31","value":11968428}],"sgaSpend":4184806,"operatingIncome":-12437291,"operatingIncomeHistory":[{"period":"2025-12-31","value":-12437291},{"period":"2024-12-31","value":-11118372},{"period":"2023-12-31","value":-11270245},{"period":"2022-12-31","value":-19791004}],"netIncome":-12163620,"netIncomeHistory":[{"period":"2025-12-31","value":-12163620},{"period":"2024-12-31","value":-10731315},{"period":"2023-12-31","value":-8236814},{"period":"2022-12-31","value":-29930694}],"eps":-0.79,"epsHistory":[{"period":"2025-12-31","value":-0.79},{"period":"2024-12-31","value":-1.19},{"period":"2023-12-31","value":-0.94},{"period":"2022-12-31","value":-3.58}],"cash":16068048,"cashHistory":[{"period":"2025-12-31","value":16068048},{"period":"2024-12-31","value":19192440},{"period":"2023-12-31","value":15111450},{"period":"2022-12-31","value":11782172}],"totalAssets":19070997,"totalLiabilities":2274183,"totalDebt":7616536,"equity":16796814,"operatingCashflow":-12014081,"operatingCashflowHistory":[{"period":"2025-12-31","value":-12014081},{"period":"2024-12-31","value":-10910324},{"period":"2023-12-31","value":-16439961},{"period":"2022-12-31","value":-26972153}],"capex":-4945136,"capexHistory":[{"period":"2022-12-31","value":-4945136},{"period":"2021-12-31","value":-3131131}],"freeCashflow":-12014081,"dividendsPaid":null,"buybacks":null,"employees":5,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":846606,"ebit":-1883994,"ebitda":-1883994,"period":"2025-12-31","revenue":0,"epsBasic":null,"netIncome":-1703210,"rdExpense":2140832,"epsDiluted":null,"grossProfit":null,"operatingIncome":-1883994},{"sga":1023821,"ebit":-2136726,"ebitda":-2136726,"period":"2025-09-30","revenue":0,"epsBasic":-0.12,"netIncome":-1998662,"rdExpense":2345843,"epsDiluted":-0.12,"grossProfit":null,"operatingIncome":-2136726},{"sga":945163,"ebit":-4261033,"ebitda":-4261033,"period":"2025-06-30","revenue":0,"epsBasic":-0.29,"netIncome":-4015564,"rdExpense":4177054,"epsDiluted":-0.29,"grossProfit":null,"operatingIncome":-4261033},{"sga":1369215,"ebit":-4155538,"ebitda":-4155538,"period":"2025-03-31","revenue":0,"epsBasic":-0.4,"netIncome":-4446184,"rdExpense":3135427,"epsDiluted":-0.4,"grossProfit":null,"operatingIncome":-4155538},{"sga":1026996,"ebit":2729663,"ebitda":2729663,"period":"2024-12-31","revenue":6591080,"epsBasic":null,"netIncome":-3837624,"rdExpense":5086184,"epsDiluted":null,"grossProfit":null,"operatingIncome":2729663},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":-0.26,"netIncome":null,"rdExpense":null,"epsDiluted":-0.26,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":1.43,"previousClose":1.43,"fiftyTwoWeekHigh":4.07,"fiftyTwoWeekLow":0.81,"fiftyTwoWeekRange":"0.81 - 4.07","fiftyDayAverage":1.44,"twoHundredDayAverage":1.31,"beta":1.43,"enterpriseValue":7774523,"forwardPE":-7.5,"priceToBook":1.42,"priceToSales":6.72,"enterpriseToRevenue":2.19,"enterpriseToEbitda":0,"pegRatio":0,"ebitda":0,"ebitdaMargin":0,"freeCashflow":-8598567,"operatingCashflow":-12014081,"totalDebt":0,"debtToEquity":0,"currentRatio":8.39,"returnOnAssets":-37.8,"returnOnEquity":-68.8,"analystRating":"","recommendationKey":"none","numberOfAnalysts":3,"targetMeanPrice":7.87,"targetHighPrice":10,"targetLowPrice":5.6,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":5.5,"institutionHeldPercent":24,"sharesOutstanding":16673127,"floatShares":13809684,"sharesShort":150562,"shortRatio":1.12,"shortPercentOfFloat":0.9,"epsTrailing":-0.79,"epsForward":-0.19,"revenuePerShare":0.23,"bookValue":1.01,"officers":[{"age":45,"name":"Dr. Juan F. Vera M.D.","title":"Co-Founder, CEO, President, Treasurer, Secretary & Director"},{"age":null,"name":"Ms. Elizabeth  Donnelly","title":"Director of Administration"},{"age":35,"name":"Dr. Maria-Bernadette  Madel Ph.D.","title":"Director of Corporate Operations & External Communications"},{"age":null,"name":"Mr. Edmund  Cheung","title":"Vice President of Human Resources"},{"age":null,"name":"Patricia  Allison","title":"Head of Clinical Operations"},{"age":66,"name":"Ms. Mary  Newman Ph.D.","title":"Head of Regulatory Affairs"},{"age":null,"name":"Dr. Robert Z. Florkiewicz Sr., Ph.D.","title":"Senior Director of Molecular Biology & Virology"}],"industry":"Biotechnology","irWebsite":"","website":"https://markertherapeutics.com","phone":"713 400 6400"}}